Soon after, two studies reported by Meyer et al. and Wu et al. characterized another Type-II JAK2 inhibitor CHZ868, which is more effective than BBT594 and exhibits striking efficacy in JAK2-dependent MPNs and B cell acute lymphoblastic leukemia (B-ALL) models26, 27. This evidence concerns the gene JAK2 and precursor B-cell acute lymphoblastic leukemia.